PG
Therapeutic Areas
Cochlear Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nucleus Platform Enhancements | Severe-to-Profound Sensorineural Hearing Loss | Continuous Development |
| Cochlear™ Acoustic Coil (CAC) | Mixed Hearing Loss | Clinical Evaluation |
| Nucleus® CI632 Slim Modiolar Electrode | Severe-to-Profound Sensorineural Hearing Loss | Commercial |
| Osia System Expansion | Conductive/Mixed Hearing Loss, Single-Sided Deafness | Commercial & Development |
| Telehealth & Remote Care Solutions | Patient Support & Clinical Efficiency | Development & Deployment |
| Hearing Health Data & AI | Performance Optimization | Research |
Leadership Team at Cochlear
DH
Dig Howitt
Chief Executive Officer & President
DR
Dr. Robert (Bob) Klapper
Chief Technology Officer
SR
Simon R. Joyce
Chief Financial Officer
HH
Heidi Hemmer
Chief Commercial Officer
BL
Brett Lee
President, Cochlear Americas
DR
Dr. Rick Holliday-Smith
Chairman of the Board